Short answer
ArriVent BioPharma, Inc. (AVBP) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$43M
- +32.7% YoY
- EPS (diluted)
- −$0.96
- +49.5% YoY
Source: XBRL data from the ArriVent BioPharma, Inc. (AVBP) Q1 2026 10-Q on SEC EDGAR. USD.
ArriVent BioPharma, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0; no product sales, unchanged from prior year
- Net loss $43.3M vs $64.4M YoY; operating margin not applicable
- Research and development expense $37.6M vs $61.3M; early-stage programs $12.3M vs $41.0M
- Cash, equivalents and marketable securities $326.4M at March 31, 2026
- ATM proceeds $54.7M; 2,425,495 shares sold during the quarter
- Cash expected to fund requirements through at least twelve months; additional financing may be required
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 rather than quarterly risk disclosures
- New financing-related filing: Loan and Security Agreement Amendment No. 1 dated March 5, 2026
- IPO proceeds $183.2 million; no material change in planned use from January 26, 2024 prospectus
- No unregistered equity sales or share repurchases during the quarter
- No directors or executives adopted, modified, or terminated Rule 10b5-1 plans during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ArriVent BioPharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.